Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

DeepDyve requires Javascript to function. Please enable Javascript on your browser to continue.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Jänne, Pasi A; Shaw, Alice T; Pereira, José Rodrigues; Jeannin, Gaëlle; Vansteenkiste, Johan;

The Lancet Oncology , Volume 14 (1): 10 – Apr 3, 2013

Download PDF

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Jänne, Pasi A; Shaw, Alice T; Pereira, José Rodrigues; Jeannin, Gaëlle; Vansteenkiste, Johan;

The Lancet Oncology , Volume 14 (1): 10 – Apr 3, 2013

Loading next page...

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN: 1470-2045
DOI: 10.1016/S1470-2045(12)70489-8
pmid: 23200175

There are no references for this article.